Juan Carlos Q Vélez, MD
@juancarlosqvelez.bsky.social
🩺 Academic Nephrologist, Ochsner Health, New Orleans, LA, USA
🎓Professor of Medicine, Ochsner Clinical School - The University of Queensland, QLD, Australia
🔬Self-proclaimed Pisse Prophet
🎓Professor of Medicine, Ochsner Clinical School - The University of Queensland, QLD, Australia
🔬Self-proclaimed Pisse Prophet
@alanyuneph.bsky.social trying to learn about CLDN2 a bit more. I was confused by the cellular localization in the proximal tubule reported in the human protein atlas: none in microvilli. As a tight junction, shouldn’t it be primarily apical?
December 12, 2025 at 3:34 AM
@alanyuneph.bsky.social trying to learn about CLDN2 a bit more. I was confused by the cellular localization in the proximal tubule reported in the human protein atlas: none in microvilli. As a tight junction, shouldn’t it be primarily apical?
Thank you again! You are leading a terrific Nephrology Division.
December 4, 2025 at 11:21 PM
Thank you again! You are leading a terrific Nephrology Division.
Reposted by Juan Carlos Q Vélez, MD
Points acknowledged but the graph allows one to see the relative changes and the shape of things that came/to come. The losartan curve is our progress vs placebo, while the others show the progress against losartan. Overall one may expect an effect similar to losartan under single agent adoption
December 1, 2025 at 2:04 AM
Points acknowledged but the graph allows one to see the relative changes and the shape of things that came/to come. The losartan curve is our progress vs placebo, while the others show the progress against losartan. Overall one may expect an effect similar to losartan under single agent adoption
Oh I’m interested. Clever and fancy. But the question is how quickly it’ll become clinically available. I suppose it’ll need further validation here in North America
November 29, 2025 at 2:06 AM
Oh I’m interested. Clever and fancy. But the question is how quickly it’ll become clinically available. I suppose it’ll need further validation here in North America
Trying to pronounce the brand name
a man with red curly hair and glasses is wearing a suit and tie and making a funny face .
ALT: a man with red curly hair and glasses is wearing a suit and tie and making a funny face .
media.tenor.com
November 26, 2025 at 1:38 AM
Trying to pronounce the brand name
Reposted by Juan Carlos Q Vélez, MD
even in their 2024 guidelines they downgrade the level of evidence for resistant hypertension.
Yes, spiro causes hyperK but that is easily managed with diuretics, especially in CKD.
Yes, spiro causes hyperK but that is easily managed with diuretics, especially in CKD.
November 23, 2025 at 4:08 PM
even in their 2024 guidelines they downgrade the level of evidence for resistant hypertension.
Yes, spiro causes hyperK but that is easily managed with diuretics, especially in CKD.
Yes, spiro causes hyperK but that is easily managed with diuretics, especially in CKD.
